


FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

 ATTY. DOCKET NO.  
1861.1640001/JMC/THN  
FIRST NAMED INVENTOR  
Donald J. Kyle

 APPLICATION NO.  
10/668,326

 FILING DATE  
September 24, 2003

 ART UNIT  
1645


## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	TRADEMARK	DATE
CA	AA1	3,536,809	10/27/1970	Applezweig				02/17/1969
CA	AB1	3,598,123	08/10/1971	Zaffaroni				04/01/1969
CA	AC1	3,845,770	11/05/1974	Theeuwes <i>et al.</i>				06/05/1972
CA	AD1	3,916,899	11/04/1975	Theeuwes <i>et al.</i>				02/07/1974
CA	AE1	4,008,719	02/22/1977	Theeuwes <i>et al.</i>				02/02/1976
CA	AF1	5,059,595	10/22/1991	Le Grazie				03/20/1990
CA	AG1	5,073,543	12/17/1991	Marshall <i>et al.</i>				07/21/1988
CA	AH1	5,120,548	06/09/1992	McClelland <i>et al.</i>				11/07/1989
CA	AI1	5,354,556	10/11/1994	Sparks <i>et al.</i>				07/09/1990
CA	AJ1	5,591,767	01/07/1997	Mohr <i>et al.</i>				06/06/1995
CA	AK1	5,639,476	06/17/1997	Oshlack <i>et al.</i>				06/02/1995

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CA	AR	1	Baumhaker, Y., and Sarne, Y., "Exposure of NG108-15 Cells to Etorphine Induces an Embedded State of the Opioid Receptor Which Discriminates Between Hydrophilic and Hydrophobic Ligands," <i>Pharmacology Communications</i> 7:149-155, Overseas Publishers Association and Harwood Academic Publishers (1996)
CA	AS	1	Brent, P.J., "Behavioural Effect of Pretreatment with Opioid Antagonists and Sigma Binding Site Ligands on the Abnormal Motor Response Produced by the Kappa Opioid Agonist U50,488H in Guinea Pigs," <i>Neuropharmacology</i> 32:751-760, Pergamon Press (1993)
CA	AT	1	Buchwald, H., <i>et al.</i> , "Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis," <i>Surgery</i> 88:507-516, The C.V. Mosby Company (1980)

EXAMINER

AULACKH

DATE CONSIDERED

4.9.04


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
1861.1640001/JMC/THN  
FIRST NAMED INVENTOR  
Donald J. Kyle  
FILING DATE  
September 24, 2003

APPLICATION NO.  
10/668,326  
ART UNIT  
1645



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
CA	AA2	5,674,533	10/07/1997	Santus <i>et al.</i>	1	1	05/26/1995
CA	AB2	5,698,155	12/16/1997	Grosswald <i>et al.</i>	1	1	01/24/1995
CA	AC2	5,733,566	03/31/1998	Lewis	1	1	10/30/1995
CA	AD2	6,294,195 B1	09/25/2001	Oshlack <i>et al.</i>	1	1	09/07/1999
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CA	AR	2	During, M.J., <i>et al.</i> , "Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization," <i>Ann. Neurol.</i> 25:351-356, Little, Brown and Company (1989)				
CA	AS	2	Foss, J.F., "A Review of the Potential Role of Methylnaltrexone in Opioid Bowel Dysfunction," <i>Am. J. Surg.</i> 182(Suppl. To November 2001):19S-26S, Excerpta Medica, Inc. (November 2001)				
CA	AT	2	Goodson, J.M., "Dental Applications," in <i>Medical Applications of Controlled Release, Volume II Applications and Evaluation</i> , Langer, R.S., and Wise, D.L., ed., CRC Press, Inc., Boca Raton, FL, pp. 115-138 (1984)				

EXAMINER

AULACH

DATE CONSIDERED

4.9.04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.


FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
1861.1640001/JMC/THN  
FIRST NAMED INVENTOR  
Donald J. Kyle  
FILING DATE  
September 24, 2003

APPLICATION NO.  
10/668,326

ART UNIT  
1645



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CA	AR	3	Griffiths, S.P., et al., "Heterogeneous Enantioselective Hydrogenation Catalysed by Platinum Modified by Some Morphine Alkaloids," in <i>Catalysis of Organic Reactions</i> , Herkes, F.E., ed., Marcel Dekker, Inc., New York, NY, pp. 89-100 (1998)
CA	AS	3	Howard III, M.A., et al., "Intracerebral drug delivery in rats with lesion-induced memory deficits," <i>J. Neurosurg.</i> 71:105-112, American Association of Neurological Surgeons (1989)
CA	AT	3	Hunskar, S., et al., "Formalin test in mice, a useful technique for evaluating mild analgesics," <i>J. Neurosci. Meth.</i> 14:69-76, Elsevier Science Publishers B.V. (1985)

EXAMINER


AULAKH

DATE CONSIDERED

4.9.04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <b>INFORMATION DISCLOSURE STATEMENT</b>		ATTY. DOCKET NO. 1861.1640001/JMC/THN FIRST NAMED INVENTOR Donald J. Kyle FILING DATE September 24, 2003	APPLICATION NO. 10/668,326 ART UNIT 1645
--	--	---	---

Page 4 of 7  


U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
CA	AR	4	Iorio, M.A., and Frigeni, V., "Narcotic agonist/antagonist properties of quaternary diastereoisomers derived from oxymorphone and naloxone," <i>Eur. J. Med. Chem. -Chim. Ther.</i> 19:301-303, Editions Scientifiques Elsevier (1984)
CA	AS	4	Langer, R., "New Methods of Drug Delivery," <i>Science</i> 249:1527-1533, American Association for the Advancement of Science (1990)
CA	AT	4	Langer, R., and Peppas, N., "Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review," <i>J. Macromol. Sci. Rev. Macromol. Chem. Phys.</i> C23:61-126, Marcel Dekker, Inc. (1983)

EXAMINER <div style="text-align: center; font-family: cursive; font-size: 1.2em;">AULAKH</div>	DATE CONSIDERED <div style="text-align: center; font-family: cursive; font-size: 1.2em;">4-9-04</div>
---	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.


FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

 ATTY. DOCKET NO.  
 1861.1640001/JMC/THN  
 FIRST NAMED INVENTOR  
 Donald J. Kyle

 FILING DATE  
 September 24, 2003

 APPLICATION NO.  
 10/668,326

 ART UNIT  
 1645


## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CA	AR	5	Leander, J.D., "A Kappa Opioid Effect: Increased Urination in the Rat," <i>J. Pharmacol. Exp. Ther.</i> 224:89-94, The American Society for Pharmacology and Experimental Therapeutics (1983)
CA	AS	5	Levy, R.J., et al., "Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate," <i>Science</i> 228:190-192, American Association for the Advancement of Science (1985)
CA	AT	5	Milne, R.J., et al., "Quaternary naloxone blocks morphine analgesia in spinal but not intact rats," <i>Neurosci. Lett.</i> 114:259-264, Elsevier Scientific Publishers Ireland Ltd. (1990)


EXAMINER

AULAKH

DATE CONSIDERED

4-9-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  <b>INFORMATION DISCLOSURE STATEMENT</b>	ATTY. DOCKET NO. 1861.1640001/JMC/THN	APPLICATION NO. 10/668,326
	FIRST NAMED INVENTOR Donald J. Kyle	
	FILING DATE September 24, 2003	ART UNIT 1645
		

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA6						
	AB6						
	AC6						
	AD6						
	AE6						
	AF6						
	AG6						
	AH6						
	AI6						
	AJ6						
	AK6						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL6						Yes No
	AM6						Yes No
	AN6						Yes No
	AO6						Yes No
	AP6						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CA	AR	6	Murphy, D.B., <i>et al.</i> , "Pharmacokinetic profile of epidurally administered methylnaltrexone, a novel peripheral opioid antagonist in a rabbit model," <i>Br. J. Anaesth.</i> 86:120-122, Oxford University Press (January 2001)
CA	AS	6	Panerai, A.E., <i>et al.</i> , "Opiates Act Centrally on GH and PRL Release," <i>Endocrinology</i> 108:2400-2402, The Endocrine Society (1981)
CA	AT	6	Saudek, C.D., <i>et al.</i> , "A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery," <i>N. Engl. J. Med.</i> 321:574-579, Massachusetts Medical Society (1989)


EXAMINER	<u>AULAKH</u>	DATE CONSIDERED	<u>4.9.04</u>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
1861.1640001/JMC/THN  
FIRST NAMED INVENTOR  
Donald J. Kyle  
FILING DATE  
September 24, 2003

APPLICATION NO.  
10/668,326  
ART UNIT  
1645



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA7						
	AB7						
	AC7						
	AD7						
	AE7						
	AF7						
	AG7						
	AH7						
	AI7						
	AJ7						
	AK7						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL7						Yes No
	AM7						Yes No
	AN7						Yes No
	AO7						Yes No
	AP7						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CA	AR	Z	Sefton, M.V., "Implantable Pumps," <i>Crit. Rev. Biomed. Eng.</i> 14:201-240, CRC Press (1987)
CA	AS	Z	Valle, L., <i>et al.</i> , "Effects of $\mu$ -opioid receptor agonists on intestinal secretion and permeability during acute intestinal inflammation in mice," <i>Eur. J. Pharmacol.</i> 389:235-242, Elsevier Science B.V. (2000)
CA	AT	Z	Yuan, C.-S., <i>et al.</i> , "Effects of Subcutaneous Methylnaltrexone on Morphine-Induced Peripherally Mediated Side Effects: A Double-Blind Randomized Placebo-Controlled Trial," <i>J. Pharmacol. Exp. Ther.</i> 300:118-123, The American Society for Pharmacology and Experimental Therapeutics (January 2002)

EXAMINER

AULLAKH

DATE CONSIDERED

4.9.04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.